Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

Samsung Bioepis collaborates with Teva to launch Epysylli in U.S. market Samsung Bioepis and Teva join forces to introduce a ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.94 which represents a decrease of $-0.55 or -2.56% from the prior close of $21.49. The stock opened at $21.27 and ...

Two Israeli stocks have been included in the top picks 2025 lists of US analysts. Bank of America chose Teva Pharmaceutical ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Members of the Knesset’s Environment Caucus host a conference in Eilat in southern Israel to protest the government’s decision last month to allow more oil to be brought into the port of the Red Sea ...